Circulating Permeability Factors in Idiopathic Nephrotic Syndrome

키워드

참고문헌 (140)

1. Eddy AA, "Nephrotic syndrome in childhood", Lancet, 362, pp.629~639 (2003)
2. Sinha A, "Nephrotic syndrome", Indian J Pediatr, 79, pp.1045~1055 (2012)
3. Vivarelli M, "Minimal change disease", Clin J Am Soc Nephrol, 12, pp.332~345 (2017)
4. Noone DG, "Idiopathic nephrotic syndrome in children", Lancet, 392(10141), pp.61~74 (2018)
5. Ha TS, "Roles of adaptor proteins in podocyte biology", World J Nephrol, 2, pp.1~10 (2013)
6. Cara-Fuentes G, "Pathogenesis of proteinuria in idiopathic minimal change disease : molecular mechanisms", Pediatr Nephrol, 31, pp.2179~2189 (2016)
7. 하태선, "Genetics of hereditary nephrotic syndrome: a clinical review", Clinical and Experimental Pediatrics, 60(3), pp.55~63 (2017), 대한소아청소년과학회
8. Shalhoub RJ, "Pathogenesis of lipoid nephrosis : a disorder of T-cell function", Lancet, 2, pp.556~560 (1974)
9. Davin JC, "The glomerular permeability factors in idiopathic nephrotic syndrome", Pediatr Nephrol, 31, pp.207~215 (2016)
10. Musante L, "Humoral permeability factors in the nephrotic syndrome:a compendium and prospectus", J Nephrol, 14(Suppl 4), pp.S48~50 (2001)
11. Lagrue G, "Transmission of nephrotic syndrome to two neonates. Spontaneous regression", Presse Med, 20, pp.255~257 (1991)
12. Kemper MJ, "Transmission of glomerular permeability factor from a mother to her child", N Engl J Med, 344, pp.386~387 (2001)
13. Zimmerman SW, "Increased urinary protein excretion in the rat produced by serum from a patient with recurrent focal glomerular sclerosis after renal transplantation", Clin Nephrol, 22, pp.32~38 (1984)
14. Sharma M, "Proteinuria after injection of human focal segmental glomerulosclerosis factor", Transplantation, 73, pp.366~372 (2002)
15. Raij L, "Steroid-resistant nephrotic syndrome : recurrence after transplantation", Ann Intern Med, 77, pp.581~586 (1972)
16. Hoyer JR, "Recurrence of idiopathic nephrotic syndrome after renal transplantation", Lancet, 2, pp.343~348 (1972)
17. Fine RN, "Recurrence of nephrotic syndrome", focal segmental glomerulosclerosis following renal transplantation in children, 2007, pp.22, 496~502
18. Zimmerman SW, "Plasmapheresis and dipyridamole for recurrent focal glomerular sclerosis", Nephron, 40, pp.241~245 (1985)
19. Artero M, "Recurrent focal glomerulosclerosis : Natural history and response to therapy", Am J Med, 92, pp.375~383 (1992)
20. Dantal J, "Effect of plasma protein adsorption on protein excretion in kidneytransplant recipients with recurrent nephrotic syndrome", N Engl J Med, 330, pp.7~14 (1994)
21. Artero ML, "Plasmapheresis reduces proteinuria and serum capacity to injure glomeruli in patients with recurrent focal glomerulosclerosis", Am J Kidney Dis, 23, pp.574~581 (1994)
22. Gohh RY, "Preemptive plasmapheresis and recurrence of FSGS in high-risk renal transplant recipients", Am J Transplant, 5, pp.2907~2912 (2005)
23. Suthar K, "Renal transplantation in primary focal segmental glomerulosclerosis using a tolerance induction protocol", Transplant Proc, 40, pp.1108~1110 (2008)
24. Gallon L, "Resolution of recurrent focal segmental glomerulosclerosis after retransplantation", N Engl J Med, 366, pp.1648~1649 (2012)
25. Rea R, "Successful transplant of a kidney with focal segmental glomerulosclerosis", Nephrol Dial Transplant, 16, pp.416~417 (2001)
26. Maas RJ, "Permeability factors in idiopathic nephrotic syndrome : historical perspectives and lessons for the future", Nephrol Dial Transplant, 29, pp.2207~2216 (2014)
27. Lagrue G, "A vascular permeability factor elaborated from lymphocytes. I. Demonstration in patients with nephrotic syndrome", Biomedicine, 23, pp.37~40 (1975)
28. Savin VJ, "Circulating factor associated with increased glomerular permeability to albumin in recurrent focal segmental glomerulosclerosis", N Engl J Med, 334, pp.878~883 (1996)
29. Kachurina N, "Novel unbiased assay for circulating podocyte-toxic factors associated with recurrent focal segmental glomerulosclerosis", Am J Physiol Renal Physiol, 310, pp.F1148~56 (2016)
30. Lennon R, "Hemopexin induces nephrin-dependent reorganization of the actin cytoskeleton in podocytes", J Am Soc Nephrol, 19, pp.2140~2149 (2008)
31. Bakker WW, "Plasma hemopexin activity in pregnancy and preeclampsia", Hypertens Pregnancy, 26, pp.227~239 (2007)
32. Savin VJ, "Measurement of albumin reflection coefficient with isolated rat glomeruli", J Am Soc Nephrol, 3, pp.1260~1269 (1992)
33. Desideri S, "A novel assay provides sensitive measurement of physiologically relevant changes in albumin permeability in isolated human and rodent glomeruli", Kidney Int, 93, pp.1086~1097 (2018)
34. Savin VJ, "Galactose binds to focal segmental glomerulosclerosis permeability factor and inhibits its activity", Transl Res, 151, pp.288~292 (2008)
35. Wang L, "A disease model of diabetic nephropathy in a glomerulus-on-a-chip microdevice", Lab Chip, 17, pp.1749~1760 (2017)
36. Koyama A, "A glomerular permeability factor produced by human T cell hybridomas", Kidney Int, 40, pp.453~460 (1991)
37. Cheung PK, "Induction of experimental proteinuria In vivo following infusion of human plasma hemopexin", Kidney Int, 57, pp.1512~1520 (2000)
38. Sharma M, "Janus kinase 2", signal transducer and activator of transcription 3 inhibitors attenuate the effect of cardiotrophin-like cytokine factor 1 and human focal segmental glomerulosclerosis serum on glomerular filtration barrier, 2015, pp.166, 384~398
39. McCarthy ET, "Circulating permeability factors in idiopathic nephrotic syndrome and focal segmental glomerulosclerosis", Clin J Am Soc Nephrol, 5, pp.2115~2121 (2010)
40. Virginia J. Savin, "Permeability factors in nephrotic syndrome and focal segmental glomerulosclerosis", Kidney Research and Clinical Practice, 31(4), pp.205~213 (2012), 대한신장학회
41. Wada T, "A circulating permeability factor in focal segmental glomerulosclerosis : the hunt continues", Clin Kidney J, 8, pp.708~715 (2015)
42. Bakker WW, "The glomerular polyanion (GPA) of the rat kidney. I. Concanavalin-A activated cells affect the glomerular polyanion in vitro", Nephron, 31, pp.68~74 (1982)
43. Bakker WW, "Loss of glomerular polyanion in vitro induced by mononuclear blood cells from patients with minimal-change nephrotic syndrome", Am J Nephrol, 6, pp.107~111 (1986)
44. Boulton-Jones JM, "Changes in the glomerular capillary wall induced by lymphocyte products and serum of nephrotic patients", Clin Nephrol, 20, pp.72~77 (1983)
45. Yoshizawa N, "Studies of a glomerular permeability factor in patients with minimal-change nephrotic syndrome", Nephron, 51, pp.370~376 (1989)
46. Bakker WW, "Altered activity of plasma hemopexin in patients with minimal change disease in relapse", Pediatr Nephrol, 20, pp.1410~1415 (2005)
47. Cheung PK, "Minimal change-like glomerular alterations induced by a human plasma factor", Nephron, 74, pp.586~593 (1996)
48. Shimada M, "Toll-like receptor 3 ligands induce CD80 expression in human podocytes via an NF-κB-dependent pathway", Nephrol Dial Transplant, 27, pp.81~89 (2012)
49. Wing K, "CTLA-4 control over Foxp3+ regulatory T cell function", Science, 322, pp.271~275 (2008)
50. Mosser DM, "Interleukin-10 : new perspectives on an old cytokine", Immunol Rev, 226, pp.205~218 (2008)
51. himada M, "Minimal change disease : a"two-hit"podocyte immune disorder", Pediatr Nephrol, 26, pp.645~649 (2011)
52. Cara-Fuentes G, "Minimal change disease : a dysregulation of the podocyte CD80-CTLA-4 axis", Pediatr Nephrol, 29, pp.2333~2340 (2014)
53. Ohl K, "CTLA4 polymorphisms in minimal change nephrotic syndrome in children : a case-control study", Am J Kidney Dis, 63, pp.1074~1075 (2014)
54. Spink C, "The CTLA-4+49GG genotype is associated with susceptibility for nephrotic kidney diseases", Nephrol Dial Transplant, 28, pp.2800~2805 (2013)
55. Cara-Fuentes G, "CD80 and suPAR in patients with minimal change disease and focal segmental glomerulosclerosis : diagnostic and pathogenic significance", Pediatr Nephrol, 29, pp.1363~1371 (2014)
56. Reiser J, "Danger signaling by glomerular podocytes defines a novel function of inducible B7-1 in the pathogenesis of nephrotic syndrome", J Am Soc Nephrol, 15, pp.2246~2248 (2004)
57. Lai KW, "Overexpression of interleukin-13 induces minimal-change-like nephropathy in rats", J Am Soc Nephrol, 18, pp.1476~1485 (2007)
58. Reiser J, "Induction of B7-1 in podocytes is associated with nephrotic syndrome", J Clin Invest, 113, pp.1390~1397 (2004)
59. Khullar B, "Interaction of CD80 with Neph1 : a potential mechanism of podocyte injury", Clin Exp Nephrol, 22, pp.508~516 (2018)
60. Ishimoto T, "Toll-like receptor 3 ligand, polyIC, induces transient proteinuria and glomerular CD80, and increases urinary CD80 in mice", Nephrol Dial Transplant, 28, pp.1439~1446 (2013)
61. Garin EH, "Urinary CD80 excretion increases in idiopathic minimal-change disease", J Am Soc Nephrol, 20, pp.260~266 (2009)[DOI]
62. Garin EH, "Urinary CD80 is elevated in minimal change disease but not in focal segmental glomerulosclerosis", Kidney Int, 78, pp.296~302 (2010)
63. Mishra OP, "Toll-like receptor 3(TLR-3), TLR-4 and CD80 expression in peripheral blood mononuclear cells and urinary CD80 levels in children with idiopathic nephrotic syndrome", Pediatr Nephrol, 32, pp.1355~1361 (2017)
64. Fiorina P, "Role of podocyte B7-1 in diabetic nephropathy", J Am Soc Nephrol, 25, pp.1415~1429 (2014)
65. Yu CC, "Abatacept in B7-1-positive proteinuric kidney disease", N Engl J Med, 369, pp.2416~2423 (2013)
66. Ishimoto T, "Serum from minimal change patients in relapse increases CD80 expression in cultured podocytes", Pediatr Nephrol, 28, pp.1803~1812 (2013)
67. Garin EH, "Case series : CTLA4-IgG1 therapy in minimal change disease and focal segmental glomerulosclerosis", Pediatr Nephrol, 30, pp.469~477 (2015)
68. Delville M, "B7-1blockade does not improve post-transplant nephrotic syndrome caused by recurrent FSGS", J Am Soc Nephrol, 27, pp.2520~2527 (2016)
69. Estreicher A, "The receptor for urokinase type plasminogen activator polarizes expression of the protease to the leading edge of migrating monocytes and promotes degradation of enzyme inhibitor complexes", J Cell Biol, 111, pp.783~792 (1990)
70. Nykjaer A, "Urokinase receptor. An activation antigen in human T lymphocytes", J Immunol, 152, pp.505~516 (1994)
71. Maas RJ, "Serum suPAR in patients with FSGS : trash or treasure", Pediatr Nephrol, 28, pp.1041~1048 (2013)
72. Roldan AL, "Cloning and expression of the receptor for human urokinase plasminogen activator, a central molecule in cell surface, plasmin dependent proteolysis", EMBO J, 9, pp.467~474 (1990)
73. Smith HW, "Regulation of cell signalling by uPAR", Nat Rev Mol Cell Biol, 11, pp.23~36 (2010)
74. Dass K, "Evolving role of uPA", uPAR system in human cancers, 2008, pp.34, 122~136
75. Wei C, "Circulating urokinase receptor as a cause of focal segmental glomerulosclerosis", Nat Med, 17, pp.952~960 (2011)
76. Kreidberg JA, "Alpha 3 beta 1 integrin has a crucial role in kidney and lung organogenesis", Development, 122, pp.3537~3547 (1996)
77. Wei C, "Modification of kidney barrier function by the urokinase receptor", Nat Med, 14, pp.55~63 (2008)
78. Wei C, "Circulating suPAR in two cohorts of primary FSGS", J Am Soc Nephrol, 23, pp.2051~2059 (2012)
79. Li F, "Relationship between serum soluble urokinase plasminogen activator receptor level and steroid responsiveness in FSGS", Clin J Am Soc Nephrol, 9, pp.1903~1911 (2014)
80. Huang J, "Plasma soluble urokinase receptor levels are increased but do not distinguish primary from secondary focal segmental glomerulosclerosis", Kidney Int, 84, pp.366~372 (2013)
81. Meijers B, "The soluble urokinase receptor is not a clinical marker for focal segmental glomerulosclerosis", Kidney Int, 85, pp.636~640 (2014)
82. Wada T, "A multicenter cross-sectional study of circulating soluble urokinase receptor in Japanese patients with glomerular disease", Kidney Int, 85, pp.641~648 (2014)
83. pinale JM, "Nephrotic Syndrome Study Network()A reassessment of soluble urokinase-type plasminogen activator receptor in glomerular disease", Kidney Int, 87, pp.564~574 (2015)
84. Maas RJ, "Serum-soluble urokinase receptor concentration in primary FSGS", Kidney Int, 81, pp.1043~1044 (2012)
85. Bock ME, "Serum soluble urokinase-type plasminogen activator receptor levels and idiopathic FSGS in children : a single-center report", Clin J Am Soc Nephrol, 8, pp.1304~1311 (2013)
86. Sinha A, "Serum-soluble urokinase receptor levels do not distinguish focal segmental glomerulosclerosis from other causes of nephrotic syndrome in children", Kidney Int, 85, pp.649~658 (2014)
87. Harita Y, "Decreased glomerular filtration as the primary factor of elevated circulating suPAR levels in focal segmental glomerulosclerosis", Pediatr Nephrol, 29, pp.1553~1560 (2014)
88. Huang J, "Urinary soluble urokinase receptor levels are elevated and pathogenic in patients with primary focal segmental glomerulosclerosis", BMC Med, 12, pp.81~ (2014)
89. Wei C, "uPAR isoform 2 forms a dimer and induces severe kidney disease in mice", J Clin Invest (2019)
90. Alfano M, "Full-length soluble urokinase plasminogen activator receptor down-modulates nephrin expression in podocytes", Sci Rep, 5, pp.13647~ (2015)
91. Delville M, "A circulating antibody panel for pretransplant prediction of FSGS recurrence after kidney transplantation", Sci Transl Med, 6, pp.256~ (2014)[DOI]
92. Cathelin D, "Administration of recombinant soluble urokinase receptor per se is not sufficient to induce podocyte alterations and proteinuria in mice", J Am Soc Nephrol, 25, pp.1662~1668 (2014)
93. Segarra-Medrano A, "Biological markers of nephrotic syndrome : a few steps forward in the long way", Nefrologia, 32, pp.558~572 (2012)
94. Kronbichler A, "Soluble urokinase receptors in focal segmental glomerulosclerosis : a review on the scientific point of view", J Immunol Res, pp.2068691~ (2016)
95. Königshausen E, "Circulating permeability factors in primary focal segmental glomerulosclerosis : A review of proposed candidates", Biomed Res Int, 2016, pp.3765608~ (2016)
96. Savin VJ, "Renal and hematological effects of CLCF-1, a B-cell-stimulating cytokine of the IL-6 family", J Immunol Res, 2015, pp.714964~ (2015)
97. Sharma M, "Janus kinase 2", signal transducer and activator of transcription 3 inhibitors attenuate the effect of cardiotrophin-like cytokine factor 1 and human focal segmental glomerulosclerosis serum on glomerular filtration barrier, 2015, pp.166, 384~398
98. Clement LC, "Circulating angiopoietin-like 4 links proteinuria with hypertriglyceridemia in nephrotic syndrome", Nat Med, 20, pp.37~46 (2014)
99. Bertelli R, "Molecular and cellular mechanisms for proteinuria in minimal change disease", Front Med(Lausanne), 5, pp.170~ (2018)
100. Chugh SS, "New insights into human minimal change disease : lessons from animal models", Am J Kidney Dis, 59, pp.284~292 (2012)
101. Ma J, "Upregulation of podocyte-secreted angiopoietin-like-4 in diabetic nephropathy", Endocrine, 49, pp.373~384 (2015)
102. Clement LC, "Podocyte-secreted angiopoietin-like-4 mediates proteinuria in glucocorticoid-sensitive nephrotic syndrome", Nat Med, 17, pp.117~122 (2011)
103. Cara-Fuentes G, "Angiopoietin-like-4 and minimal change disease", PLoS One, 12, pp.e0176198~ (2017)
104. Macé C, "Nephrotic syndrome : components, connections, and angiopoietin-like 4-related therapeutics", J Am Soc Nephrol, 25, pp.2393~2398 (2014)
105. Chugh SS, "Angiopoietin-like 4 based therapeutics for proteinuria and kidney disease", Front Pharmacol, 5, pp.23~ (2014)
106. McKenzie AN, "Interleukin 13, a T-cell-derived cytokine that regulates human monocyte and B-cell function", Proc Natl Acad Sci USA, 90, pp.3735~3740 (1993)
107. Yap HK, "Th1and Th2 cytokine mRNA profiles in childhood nephrotic syndrome : evidence for increased IL-13 mRNA expression in relapse", J Am Soc Nephrol, 10, pp.529~537 (1999)
108. Cheung W, "Atopy, serum IgE, and interleukin-13 in steroid-responsive nephrotic syndrome", Pediatr Nephrol, 19, pp.627~632 (2004)
109. Chen SP, "Childhood nephrotic syndrome in relapse is associated with down-regulation of monocyte CD14 expression and lipopolysaccharide-induced tumour necrosis factor-alpha production", Clin Exp Immunol, 134, pp.111~119 (2003)
110. 박세진, "Effects of Interleukin-13 and Montelukast on the Expression of Zonula Occludens-1 in Human Podocytes", Yonsei Medical Journal, 56(2), pp.426~432 (2015), 연세대학교의과대학[DOI]
111. Ha TS, "Montelukast improves the changes of cytoskeletal and adaptor proteins of human podocytes by interleukin-13", Inflamm Res, 66, pp.793~802 (2017)
112. 이금화, "Interleukin-13 Increases Podocyte Apoptosis in Cultured Human Podocytes", Childhood Kidney Diseases, 22(1), pp.22~27 (2018), 대한소아신장학회
113. Kanai T, "Th2cells predominate in idiopathic steroid-sensitive nephrotic syndrome", Clin Exp Nephrol, 14, pp.578~583 (2010)
114. Bagnasco D, "A critical evaluation of anti-IL-13 and anti-IL-4 strategies in severe asthma", Int Arch Allergy Immunol, 170, pp.122~131 (2016)
115. Matsunaga MC, "IL-4 and IL-13 inhibition in atopic dermatitis", J Drugs Dermatol, 15, pp.925~929 (2016)
116. Garin EH, "IL-8 production by peripheral blood mononuclear cells in nephrotic patients", Kidney Int, 45, pp.1311~1317 (1994)
117. Cho MH, "Interleukin-8 and tumor necrosis factor-alpha are increased in minimal change disease but do not alter albumin permeability", Am J Nephrol, 23, pp.260~266 (2003)
118. Souto MF, "Immune mediators in idiopathic nephrotic syndrome : evidence for a relation between interleukin 8 and proteinuria", Pediatr Res, 64, pp.637~642 (2008)
119. Garin EH, "Anti-interleukin 8 antibody abolishes effects of lipoid nephrosis cytokine", Pediatr Nephrol, 12, pp.381~385 (1998)
120. Garin EH, "Effect of interleukin-8 on glomerular sulfated compounds and albuminuria", Pediatr Nephrol, 11, pp.274~279 (1997)
121. Quezada SA, "CD40", CD154 interactions at the interface of tolerance and immunity, 2004, pp.22, 307~328
122. Hassan GS, "CD40 ligand : a neo-inflammatory molecule in vascular diseases", Immunobiology, 217, pp.521~532 (2012)
123. Delville M, "A circulating antibody panel for pretransplant prediction of FSGS recurrence after kidney transplantation", Sci Transl Med, 6, pp.256~ (2014)[DOI]
124. Kairaitis L, "Blockade of CD40-CD40 ligand protects against renal injury in chronic proteinuric renal disease", Kidney Int, 64, pp.1265~1272 (2003)
125. Doublier S, "Soluble CD40 ligand directly alters glomerular permeability and may act as a circulating permeability factor in FSGS", PLoS One, 12, pp.e0188045~ (2017)
126. Lee VW, "The CD40-CD154 co-stimulation pathway mediates innate immune injury in adriamycin nephrosis", Nephrol Dial Transplant, 25, pp.717~730 (2010)
127. Kairaitis L, "Blockade of CD40-CD40 ligand protects against renal injury in chronic proteinuric renal disease", Kidney Int, 64, pp.1265~1272 (2003)
128. van den Hoven MJ, "Heparanase in glomerular diseases", Kidney Int, 72, pp.543~548 (2007)
129. Holt RC, "Heparanase activity is dysregulated in children with steroid-sensitive nephrotic syndrome", Kidney Int, 67, pp.122~129 (2005)
130. Katz A, "Involvement of human heparanase in the pathogenesis of diabetic nephropathy", Isr Med Assoc J, 4, pp.996~1002 (2002)
131. van den Hoven MJ, "Increased expression of heparanase in overt diabetic nephropathy", Kidney Int, 70, pp.2100~2108 (2006)
132. Szymczak M, "The role of heparanase in diseases of the glomeruli", Arch Immunol Ther Exp(Warsz), 58, pp.45~56 (2010)
133. Levidiotis V, "Heparanase inhibition reduces proteinuria in a model of accelerated anti-glomerular basement membrane antibody disease", Nephrology(Carlton), 10, pp.167~173 (2005)
134. Raats CJ, "Reduction in glomerular heparin sulfate correlates with complement deposition and albuminuria in active Heymann nephritis", J Am Soc Nephrol, 10, pp.1689~1699 (1999)
135. Levidiotis V, "Heparanase is involved in the pathogenesis of proteinuria as a result of glomerulonephritis", J Am Soc Nephrol, 15, pp.68~78 (2004)
136. Levidiotis V, "A synthetic heparanase inhibitor reduces proteinuria in passive Heymann nephritis", J Am Soc Nephrol, 15, pp.2882~2892 (2004)
137. Levidiotis V, "Increased expression of heparanase in puromycin aminonucleoside nephrosis", Kidney Int, 60, pp.1287~1296 (2001)
138. Kramer A, "Induction of glomerular heparanase expression in rats with adriamycin nephropathy is regulated by reactive oxygen species and the renin-angiotensin system", J Am Soc Nephrol, 17, pp.2513~2520 (2006)
139. van den Hoven MJ, "Reduction of anionic sites in the glomerular basement membrane by heparanase does not lead to proteinuria", Kidney Int, 73, pp.278~287 (2008)
140. Assady S, "Nephroprotective effect of heparanase in experimental nephrotic syndrome", PLoS One, 10, pp.e0119610~ (2015)

관련 논문AI추천